Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model

New Drugs for Chronic Myelogenous Leukemia

(2011) Fabio P. S. Santos et al.   Current Hematologic Malignancy Reports

3-Cyano-6-(5-methyl-3-pyrazoloamino)pyridines: Selective Aurora A kinase inhibitors

(2010) Ryoichi Ando et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib

(2010) Kevin R. Kelly et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia

(2009) Nicholas J. Donato et al.   BIOCHEMICAL PHARMACOLOGY

BCR-ABLGene Expression Is Required for Its Mutations in a Novel KCL-22 Cell Culture Model for Acquired Resistance of Chronic Myelogenous Leukemia

(2009) Hongfeng Yuan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A Class of 2,4-Bisanilinopyrimidine Aurora A Inhibitors with Unusually High Selectivity against Aurora B†

(2009) Ignacio Aliagas-Martin et al.   JOURNAL OF MEDICINAL CHEMISTRY

Cotreatment with Vorinostat Enhances Activity of MK-0457 (VX-680) against Acute and Chronic Myelogenous Leukemia Cells

(2008) W. Fiskus et al.   CLINICAL CANCER RESEARCH

Aurora A Is Essential for Early Embryonic Development and Tumor Suppression

(2008) Lin-Yu Lu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Aurora A overexpression induces cellular senescence in mammary gland hyperplastic tumors developed in p53-deficient mice

(2008) D Zhang et al.   ONCOGENE